search button

Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis

  • Authors:
    • Hirofumi Akita
    • Shigeru Marubashi
    • Hiroshi Wada
    • Naoki Hama
    • Koichi Kawamoto
    • Shogo Kobayashi
    • Hidetoshi Eguchi
    • Yuichiro Doki
    • Masaki Mori
    • Hiroaki Nagano

  • View Affiliations

  • Published online on: November 21, 2014     https://doi.org/10.3892/mco.2014.463
  • Pages: 322-328
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Managing extrahepatic recurrence in hepatocellular carcinoma (HCC) patients is crucial for improving prognosis. The present study aimed to investigate the effectiveness of using combination therapy with S‑1 and interferon (IFN)‑α in HCC patients with lung metastasis. Of the 646 patients who underwent radical surgery for HCC at our institute, 62 developed their first distant metastasis in the lung. Among these patients, 11 received S‑1 combination therapy, while the remaining 51 patients received other conventional therapy, such as 5‑fluorouracil and cisplatin or best supportive care. We retrospectively evaluated the toxicity and efficiency of combination therapy with S‑1 and IFN‑α. Hematological toxicity was observed in 5 patients and was grade 1 or 2 in all cases, except 1 patient (9.1%) who developed grade 3 leukopenia. Non‑hematological toxicity was observed in 6 patients and was grade 1 in all cases, except 1 patient who exhibited a grade 2 increase of serum bilirubin levels. No patient required discontinuation of the S‑1 combination therapy and no treatment‑related mortality was reported during this study. Patients who received S‑1 treatment exhibited significantly better survival after distant recurrence (SADR) compared to those without S‑1 treatment (3‑year survival rate, 81.8 vs. 43.1%, respectively; P=0.014). The multivariate analysis revealed that the S‑1 treatment was prognostically significant for SADR (P=0.0091; hazard ratio = 0.343). In conclusion, combination therapy with S‑1 and IFN‑α may be efficient for HCC patients with lung metastasis.
View Figures
View References

Related Articles

Journal Cover

March-2015
Volume 3 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Akita H, Marubashi S, Wada H, Hama N, Kawamoto K, Kobayashi S, Eguchi H, Doki Y, Mori M, Nagano H, Nagano H, et al: Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis. Mol Clin Oncol 3: 322-328, 2015
APA
Akita, H., Marubashi, S., Wada, H., Hama, N., Kawamoto, K., Kobayashi, S. ... Nagano, H. (2015). Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis. Molecular and Clinical Oncology, 3, 322-328. https://doi.org/10.3892/mco.2014.463
MLA
Akita, H., Marubashi, S., Wada, H., Hama, N., Kawamoto, K., Kobayashi, S., Eguchi, H., Doki, Y., Mori, M., Nagano, H."Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis". Molecular and Clinical Oncology 3.2 (2015): 322-328.
Chicago
Akita, H., Marubashi, S., Wada, H., Hama, N., Kawamoto, K., Kobayashi, S., Eguchi, H., Doki, Y., Mori, M., Nagano, H."Combination therapy with S-1 and interferon-α in hepatocellular carcinoma patients with lung metastasis". Molecular and Clinical Oncology 3, no. 2 (2015): 322-328. https://doi.org/10.3892/mco.2014.463